Patients undergoing surgery who are taking DPP-4 inhibitors (-gliptins) and GLP-1 analogues (-tides) can continue taking these medications as normal throughout the perioperative period. However, SGLT-2 blockers such as empagliflozin and dapagliflozin should be omitted on the day of surgery due to the increased risk of diabetic ketoacidosis during periods of dehydration and acute illness. Sulphonylureas like gliclazide should also be omitted until the patient is able to eat and drink again, as they can cause hypoglycaemia in patients who are in a fasted state. It is important to note that the patient in the case scenario may have been taking sulphonylureas in the past, but they are unlikely to be part of their current treatment regimen as they were discontinued by their GP due to side effects.

Preparation for surgery varies depending on whether the patient is undergoing an elective or emergency procedure. For elective cases, it is important to address any medical issues beforehand through a pre-admission clinic. Blood tests, urine analysis, and other diagnostic tests may be necessary depending on the proposed procedure and patient fitness. Risk factors for deep vein thrombosis should also be assessed, and a plan for thromboprophylaxis formulated. Patients are advised to fast from non-clear liquids and food for at least 6 hours before surgery, and those with diabetes require special management to avoid potential complications. Emergency cases require stabilization and resuscitation as needed, and antibiotics may be necessary. Special preparation may also be required for certain procedures, such as vocal cord checks for thyroid surgery or bowel preparation for colorectal cases.

The most likely cause of bilious vomiting on the first day of life is intestinal atresia. This is because the presence of bilious vomiting in early life suggests a bowel obstruction, and the fact that it has occurred on the first day of life indicates an underlying structural issue. Children with Down’s syndrome are at a higher risk of developing this condition, especially at the duodenum. The diagnosis of intestinal/duodenal atresia is further supported by the presence of the ‘double bubble’ on the x-ray.

Biliary atresia is an incorrect answer as it would not cause the clinical picture described above. This condition results in neonatal jaundice beyond 14 days of life, with dark urine and pale stools.

Malrotation with volvulus is also an incorrect answer. While it can cause bilious vomiting, it tends to present around 3 to 7 days following birth.

Necrotising enterocolitis is another incorrect answer. Although it can cause bilious vomiting, it typically does not occur so early following birth. Additionally, it is usually a condition of prematurity and is rarely seen in infants born at term.

Causes and Treatments for Bilious Vomiting in Neonates

Bilious vomiting in neonates can be caused by various disorders, including duodenal atresia, malrotation with volvulus, jejunal/ileal atresia, meconium ileus, and necrotising enterocolitis. Duodenal atresia occurs in 1 in 5000 births and is more common in babies with Down syndrome. It typically presents a few hours after birth and can be diagnosed through an abdominal X-ray that shows a double bubble sign. Treatment involves duodenoduodenostomy. Malrotation with volvulus is usually caused by incomplete rotation during embryogenesis and presents between 3-7 days after birth. An upper GI contrast study or ultrasound can confirm the diagnosis, and treatment involves Ladd’s procedure. Jejunal/ileal atresia is caused by vascular insufficiency in utero and occurs in 1 in 3000 births. It presents within 24 hours of birth and can be diagnosed through an abdominal X-ray that shows air-fluid levels. Treatment involves laparotomy with primary resection and anastomosis. Meconium ileus occurs in 15-20% of babies with cystic fibrosis and presents in the first 24-48 hours of life with abdominal distension and bilious vomiting. Diagnosis involves an abdominal X-ray that shows air-fluid levels, and a sweat test can confirm cystic fibrosis. Treatment involves surgical decompression, and segmental resection may be necessary for serosal damage. Necrotising enterocolitis occurs in up to 2.4 per 1000 births, with increased risks in prematurity and inter-current illness. It typically presents in the second week of life and can be diagnosed through an abdominal X-ray that shows dilated bowel loops, pneumatosis, and portal venous air. Treatment involves conservative and supportive measures for non-perforated cases, while laparotomy and resection are necessary for perforated cases or ongoing clinical deterioration.

The patient likely has pilonidal disease, causing recurrent pain and discharge in the natal cleft. Surgery is the definitive management, while antibiotics and incision and drainage may provide temporary relief. Maintaining personal hygiene and hair removal can prevent future recurrences.

Understanding Pilonidal Disease

Pilonidal disease is a common condition that affects the upper part of the natal cleft of the buttocks. It is more prevalent in men and usually occurs around the age of 20 years. The disease is believed to develop when hair debris accumulates in intergluteal pores, which become stretched when a person sits or bends. Over time, this can lead to the formation of sinuses, with more hairs becoming trapped within the sinus. The sinus opening is lined by squamous epithelium, but most of its wall consists of granulation tissue.

When acute inflammation occurs, pilonidal disease typically presents as a sinus, causing severe pain, purulent discharge, and a fluctuant swelling at the site. Patients may experience cycles of being asymptomatic and periods of pain and discharge from the sinus. Asymptomatic patients can be managed conservatively, with a focus on local hygiene. Symptomatic patients may require incision and drainage if the disease is acute, allowing the wound to close by secondary intention. Surgical options, including excision of the pits and obliteration of the underlying cavity, may be necessary for chronic or recurrent cases.

March Fracture: A Common Injury in Active Individuals

March fracture is a type of stress fracture that affects the metatarsals, commonly seen in individuals who engage in repetitive activities such as running or walking. This injury is often observed in army recruits, nurses, and runners. One of the primary symptoms of March fracture is the development of a tender lump on the back of the foot, which can be felt just below the midshaft of a metatarsal bone, usually the second one.

While early radiology tests may not show any abnormalities, later tests may reveal a hairline fracture or the formation of callus in more severe cases. Fortunately, March fracture does not cause any displacement, so there is no need for reduction or splinting. Instead, normal walking is encouraged, and the forefoot may be supported with elastoplast to alleviate pain.

It typically takes around five to six weeks for the pain to subside, as the fracture heals and unites. the symptoms and treatment options for March fracture can help individuals who engage in repetitive activities take the necessary precautions to prevent this common injury.

Malrotation is most commonly seen in neonates within the first 30 days of life, and it often presents with bilious vomiting. The abdomen may initially be soft and non-tender, but if left untreated, it can lead to gut strangulation. In this scenario, the child’s distended and firm abdomen and lack of stool suggest this complication.

Appendicitis is rare in neonates and becomes more common in children over 3 years old. Symptoms of appendicitis in children typically include right-sided abdominal pain, fever, anorexia, and vomiting. Bilious vomiting, as seen in this case, would be unusual unless the condition had been present for a long time.

Necrotising enterocolitis usually presents in neonates with abdominal pain, swelling, diarrhoea with bloody stool, green/yellow vomit, lethargy, refusal to eat, and lack of weight gain. It is more common in premature babies and tends to have a more gradual onset, rather than presenting as an acutely unwell and dehydrated neonate.

Vomiting associated with pyloric stenosis is typically non-bilious and projectile, and it usually occurs between 4-8 weeks of age. Weight loss and dehydration are common at presentation, and visible peristalsis and a palpable olive-sized pyloric mass may be felt during a feed. Lack of ability to pass stool and a distended abdomen are not typical features of this condition.

Causes and Treatments for Bilious Vomiting in Neonates

Bilious vomiting in neonates can be caused by various disorders, including duodenal atresia, malrotation with volvulus, jejunal/ileal atresia, meconium ileus, and necrotising enterocolitis. Duodenal atresia occurs in 1 in 5000 births and is more common in babies with Down syndrome. It typically presents a few hours after birth and can be diagnosed through an abdominal X-ray that shows a double bubble sign. Treatment involves duodenoduodenostomy. Malrotation with volvulus is usually caused by incomplete rotation during embryogenesis and presents between 3-7 days after birth. An upper GI contrast study or ultrasound can confirm the diagnosis, and treatment involves Ladd’s procedure. Jejunal/ileal atresia is caused by vascular insufficiency in utero and occurs in 1 in 3000 births. It presents within 24 hours of birth and can be diagnosed through an abdominal X-ray that shows air-fluid levels. Treatment involves laparotomy with primary resection and anastomosis. Meconium ileus occurs in 15-20% of babies with cystic fibrosis and presents in the first 24-48 hours of life with abdominal distension and bilious vomiting. Diagnosis involves an abdominal X-ray that shows air-fluid levels, and a sweat test can confirm cystic fibrosis. Treatment involves surgical decompression, and segmental resection may be necessary for serosal damage. Necrotising enterocolitis occurs in up to 2.4 per 1000 births, with increased risks in prematurity and inter-current illness. It typically presents in the second week of life and can be diagnosed through an abdominal X-ray that shows dilated bowel loops, pneumatosis, and portal venous air. Treatment involves conservative and supportive measures for non-perforated cases, while laparotomy and resection are necessary for perforated cases or ongoing clinical deterioration.

GnRH agonists used in the treatment of prostate cancer may lead to a ‘tumour flare’ when initiated, resulting in symptoms such as bone pain and bladder obstruction. To prevent this paradoxical increase in symptoms, anti-androgens are used. GnRH agonists initially cause an increase in luteinizing hormone secretion, which stimulates the production of testosterone by Leydig cells in the testicles. Testosterone promotes the growth and survival of prostate cancer cells, leading to an increase in symptoms. Anti-androgens work by blocking androgen receptors, preventing testosterone from binding to them and suppressing luteinizing hormone secretion, thereby reducing testosterone levels and preventing ‘tumour flare’. Anti-androgens do not directly affect tumour growth rate.

Management of Prostate Cancer

Localised prostate cancer (T1/T2) can be managed through various treatment options depending on the patient’s life expectancy and preference. Conservative approaches such as active monitoring and watchful waiting can be considered, as well as radical prostatectomy and radiotherapy (external beam and brachytherapy). On the other hand, localised advanced prostate cancer (T3/T4) may require hormonal therapy, radical prostatectomy, or radiotherapy. However, patients who undergo radiotherapy may develop proctitis and are at a higher risk of bladder, colon, and rectal cancer.

For metastatic prostate cancer, the primary goal is to reduce androgen levels. A combination of approaches is often used, including anti-androgen therapy, synthetic GnRH agonist or antagonists, bicalutamide, cyproterone acetate, abiraterone, and bilateral orchidectomy. GnRH agonists such as Goserelin (Zoladex) may result in lower LH levels longer term by causing overstimulation, which disrupts endogenous hormonal feedback systems. This may cause a rise in testosterone initially for around 2-3 weeks before falling to castration levels. To prevent a rise in testosterone, anti-androgen therapy is often used initially. However, this may result in a tumour flare, which stimulates prostate cancer growth and may cause bone pain, bladder obstruction, and other symptoms. GnRH antagonists such as degarelix are being evaluated to suppress testosterone while avoiding the flare phenomenon. Chemotherapy with docetaxel may also be an option for the treatment of hormone-relapsed metastatic prostate cancer in patients who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated.

The Gleason score is utilized to grade prostate cancer based on its histology, with a score of 10 indicating a highly aggressive form of the disease. Gynecological malignancies are staged using the FIGO system, while the EuroQOL score serves as a tool for measuring quality of life.

Prostate cancer is a common condition that affects up to 30,000 men each year in the UK, with up to 9,000 dying from the disease annually. Early prostate cancers often have few symptoms, while metastatic disease may present as bone pain and locally advanced disease may present as pelvic pain or urinary symptoms. Diagnosis involves prostate specific antigen measurement, digital rectal examination, trans rectal USS (+/- biopsy), and MRI/CT and bone scan for staging. The normal upper limit for PSA is 4ng/ml, but false positives may occur due to prostatitis, UTI, BPH, or vigorous DRE. Pathology shows that 95% of prostate cancers are adenocarcinomas, and grading is done using the Gleason grading system. Treatment options include watchful waiting, radiotherapy, surgery, and hormonal therapy. The National Institute for Clinical Excellence (NICE) recommends active surveillance as the preferred option for low-risk men, with treatment decisions made based on the individual’s co-morbidities and life expectancy.

Women who are taking hormone replacement therapy, such as Femoston, should discontinue its use four weeks prior to any elective surgeries. This is because the risk of venous thromboembolism increases with the use of HRT. It is important to note that no changes are necessary for medications such as labetalol and amlodipine, as they are safe to continue taking before and on the day of surgery. Additionally, levothyroxine is also safe to take before and on the day of surgery, so there is no need to discontinue its use one week prior to the procedure.

Venous thromboembolism (VTE) is a serious condition that can lead to severe health complications and even death. However, it is preventable. The National Institute for Health and Care Excellence (NICE) has updated its guidelines for 2018 to provide recommendations for the assessment and management of patients at risk of VTE in hospital. All patients admitted to the hospital should be assessed individually to identify risk factors for VTE development and bleeding risk. The department of health’s VTE risk assessment tool is recommended for medical and surgical patients. Patients with certain risk factors, such as reduced mobility, surgery, cancer, and comorbidities, are at increased risk of developing VTE. After assessing a patient’s VTE risk, healthcare professionals should compare it to their risk of bleeding to decide whether VTE prophylaxis should be offered. If indicated, VTE prophylaxis should be started as soon as possible.

There are two types of VTE prophylaxis: mechanical and pharmacological. Mechanical prophylaxis includes anti-embolism stockings and intermittent pneumatic compression devices. Pharmacological prophylaxis includes fondaparinux sodium, low molecular weight heparin (LMWH), and unfractionated heparin (UFH). The choice of prophylaxis depends on the patient’s individual risk factors and bleeding risk.

In general, medical patients deemed at risk of VTE after individual assessment are started on pharmacological VTE prophylaxis, provided that the risk of VTE outweighs the risk of bleeding and there are no contraindications. Surgical patients at low risk of VTE are treated with anti-embolism stockings, while those at high risk are treated with a combination of stockings and pharmacological prophylaxis.

Patients undergoing certain surgical procedures, such as hip and knee replacements, are recommended to receive pharmacological VTE prophylaxis to reduce the risk of VTE developing post-surgery. For fragility fractures of the pelvis, hip, and proximal femur, LMWH or fondaparinux sodium is recommended for a month if the risk of VTE outweighs the risk of bleeding.

Healthcare professionals should advise patients to stop taking their combined oral contraceptive pill or hormone replacement therapy four weeks before surgery and mobilize them as soon as possible after surgery. Patients should also ensure they are hydrated. By following these guidelines, healthcare professionals can help prevent VTE and improve patient outcomes.

Blood stained discharge is most commonly associated with an intraductal papilloma, which is a benign tumor that develops within the lactating ducts. Surgical excision is the recommended treatment, with histology to check for any signs of breast cancer.

Breast fat necrosis, on the other hand, is typically caused by trauma and presents as a firm, round lump within the breast tissue. It is not associated with nipple discharge and usually resolves on its own.

Fibroadenomas, or breast mice, are also benign lumps that are small, non-tender, and mobile. They do not require treatment and are not associated with nipple discharge.

Mammary duct ectasia is a condition where a breast duct becomes dilated, often resulting in blockage. It can cause nipple discharge, but this is typically thick, non-bloody, and green in color. Although bloody discharge can occur, it is less likely than with intraductal papilloma. Mammary duct ectasia is usually self-limiting, but surgery may be necessary in some cases.

Pituitary prolactinoma is a possible differential diagnosis, but the nipple discharge would be bilateral and non-blood stained. Larger prolactinomas can also cause bitemporal hemianopia due to compression of the optic chiasm.

Understanding Nipple Discharge: Causes and Assessment

Nipple discharge is a common concern among women, and it can be caused by various factors. Physiological discharge occurs during breastfeeding, while galactorrhea may be triggered by emotional events or certain medications. Hyperprolactinemia, which is often associated with pituitary tumors, can also cause nipple discharge. Mammary duct ectasia, which is characterized by the dilation of breast ducts, is common among menopausal women and smokers. On the other hand, nipple discharge may also be a sign of more serious conditions such as carcinoma or intraductal papilloma.

To assess patients with nipple discharge, a breast examination is necessary to determine the presence of a mass lesion. If a mass lesion is suspected, triple assessment is recommended. Reporting of investigations follows a system that uses a prefix denoting the type of investigation and a numerical code indicating the abnormality found. For non-malignant nipple discharge, endocrine disease should be excluded, and smoking cessation advice may be given for duct ectasia. In severe cases of duct ectasia, total duct excision may be necessary.

Understanding the causes and assessment of nipple discharge is crucial in providing appropriate management and treatment. It is important to seek medical attention if nipple discharge persists or is accompanied by other symptoms such as pain or a lump in the breast.

An ileostomy is a type of stoma that is created to prevent the skin from being exposed to the enzymes in the small intestine. This is commonly seen in patients with Crohn’s disease, which affects the entire gastrointestinal tract. While the location of the stoma may vary, it is the structure of the stoma itself that determines whether it is an ileostomy or a colostomy. In contrast, a tracheostomy is an opening in the trachea, while a nephrostomy is an opening in the kidneys that is used to drain urine into a bag. A urostomy is another type of stoma that is used to divert urine from the urinary system into a bag, but it differs from an ileostomy in that it involves the use of an ileal conduit.

Abdominal stomas are created during various abdominal procedures to bring the lumen or contents of organs onto the skin. Typically, this involves the bowel, but other organs may also be diverted if necessary. The type and method of construction of the stoma will depend on the contents of the bowel. Small bowel stomas should be sprouted to prevent irritant contents from coming into contact with the skin, while colonic stomas do not require spouting. Proper siting of the stoma is crucial to reduce the risk of leakage and subsequent maceration of the surrounding skin. The type and location of the stoma will vary depending on the purpose, such as defunctioning the colon or providing feeding access. Overall, abdominal stomas are a necessary medical intervention that requires careful consideration and planning.